Condition: Myopia · Children · Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Prevalence of myopia and its complications has been increasing over the past decades, especially among children and adolescents. It reaches record levels in Asia: nearly 80% of the population in some regions in 2012 where the investigators speak in terms of epidemic. ATROPINE 0.01% eyedrops one drop per day is today an evolutive myopia treatment, whose results are promising. The investigators use this eye drops in our clinical practice at hospital of Saint-Etienne since 2017. Few clinical data have been published so far concerning the French population. The investigators would like to build a database so that the investigators can publish our results and share our experience.
This description comes directly from the study's public registry record.
Marie Caroline TRONE · 04 77 82 94 28 · m.caroline.trone@chu-st-etienne.fr
Marie PEURIERE · 04 77 82 92 72 · marie.peuriere@chu-st-etienne.fr
Always discuss trial participation with your own doctor first.
| CHU de Saint Etienne | Saint-Etienne, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04252989